Oxidative stress and prostatic diseases (Review)
- Authors:
- Thierry Roumeguère
- Joseph Sfeir
- Elie El Rassy
- Simone Albisinni
- Pierre van Antwerpen
- Karim Zouaoui Boudjeltia
- Nassim Farès
- Joseph Kattan
- Fouad Aoun
-
Affiliations: Department of Urology, University Clinics of Brussels, Université Libre de Bruxelles, Erasme Hôpital, 187793 Bruxelles, Belgium, Department of Urology, Hôtel‑Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon, Department of Oncology, Hôtel‑Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon, Laboratory of Experimental Medicine, Unit 222, Université Libre de Bruxelles, Le Centre Hospitalier Universitaire de Charleroi, 6042 Charleroi, Belgium, Research Laboratory of Physiology and PathoPhysiology, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon - Published online on: September 19, 2017 https://doi.org/10.3892/mco.2017.1413
- Pages: 723-728
-
Copyright: © Roumeguère et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Lebret T, Culine S, Davin JL, Hennequin C, Mignard JP, Moreau JL, Rossi D, Zerbib M, Mahmoudi A and Latorzeff I: Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: Results of a French observational study. Aging Male. 17:87–93. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Aoun F, Marcelis Q and Roumeguère T: Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: Technology update. Res Rep Urol. 7:125–136. 2015.PubMed/NCBI | |
|
Kullisaar T, Türk S, Punab M and Mändar R: Oxidative stress-cause or consequence of male genital tract disorders? Prostate. 72:977–983. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Aoun F, Albisinni S, Chemaly AK, Zanaty M and Roumeguère T: In search for a common pathway for health issues in men-the sign of a holmesian deduction. Asian Pac J Cancer Prev. 17:1–13. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bostanci Y, Kazzazi A, Momtahen S, Laze J and Djavan B: Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 23:5–10. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chughtai B, Lee R, Te A and Kaplan S: Role of inflammation in benign prostatic hyperplasia. Rev Urol. 13:147–150. 2011.PubMed/NCBI | |
|
Sciarra A, Mariotti G, Salciccia S, Gomez Autran A, Monti S, Toscano V and Di Silverio F: Prostate growth and inflammation. J Steroid Biochem Mol Biol. 108:254–260. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hamid AR, Umbas R and Mochtar CA: Recent role of inflammation in prostate diseases: Chemoprevention development opportunity. Acta Med Indones. 43:59–65. 2011.PubMed/NCBI | |
|
Wong CP, Bray TM and Ho E: Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett. 276:38–46. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Meagher EA and FitzGerald GA: Indices of lipid peroxidation in vivo: Strengths and limitations. Free Radic Biol Med. 28:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, Fraccica G and Gangemi S: Malondialdehyde in benign prostate hypertrophy: A useful marker? Mediators Inflamm. 12:127–128. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, Miano L and Ciancarelli Tozzi MG: Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int. 85:328–333. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, Banev S, Petrovski D, Dzikova S, Georgiev V, et al: Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. 42:1228–1235. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Almushatat AS, Talwar D, McArdle PA, Williamson C, Sattar N, O'Reilly DS, Underwood MA and McMillan DC: Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer. Int J Cancer. 118:1051–1053. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Vital P, Castro P and Ittmann M: Oxidative stress promotes benign prostatic hyperplasia. Prostate. 76:58–67. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Massey KJ, Hong NJ and Garvin JL: Angiotensin II stimulates superoxide production in the thick ascending limb by activating NOX4. Am J Physiol Cell Physiol. 303:C781–C789. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Verbon EH, Post JA and Boonstra J: The influence of reactive oxygen species on cell cycle progression in mammalian cells. Gene. 511:1–6. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nassis L, Frauman AG, Ohishi M, Zhuo J, Casley DJ, Johnston CI and Fabiani ME: Localization of angiotensin-converting enzyme in the human prostate: Pathological expression in benign prostatic hyperplasia. J Pathol. 195:571–579. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Klebanoff SJ: Myeloperoxidase: Friend and foe. J Leukoc Biol. 77:598–625. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Boudjeltia KZ, Legssyer I, Van Antwerpen P, Kisoka RL, Babar S, Moguilevsky N, Delree P, Ducobu J, Remacle C, Vanhaeverbeek M and Brohee D: Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol. 84:805–812. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Roumeguère T, Delree P, Van Antwerpen P, Rorive S, Vanhamme L, de Ryhove Lde L, Serteyn D, Wespes E, Vanhaerverbeek M and Boudjeltia KZ: Intriguing location of myeloperoxidase in the prostate: A preliminary immunohistochemical study. Prostate. 72:507–513. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Boudjeltia KZ, Delporte C, Van Antwerpen P, Franck T, Serteyn D, Moguilevsky N, Raes M, Vanhamme L, Vanhaeverbeek M, Van Meerhaeghe A and Roumeguère T: Myeloperoxidase-dependent LDL modifications in bloodstream are mainly predicted by angiotensin II, adiponectin, and myeloperoxidase activity: A cross-sectional study in men. Mediators Inflamm. 2013:7507422013.PubMed/NCBI | |
|
Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J and Bartek J: DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. Mol Oncol. 10:879–894. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP and Ghosh R: NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res. 74:5644–5655. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G and Basu HS: Expression of spermidine/spermine N(1)-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 75:1150–1159. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S and Jarrard DF: A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PloS One. 9:e880522014. View Article : Google Scholar : PubMed/NCBI | |
|
Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J, Zalazar F, Navone N, et al: Association of HO-1 and BRCA1 is critical for the maintenance of cellular homeostasis in prostate cancer. Mol Cancer Res. 13:1455–1464. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Basu A, Ross Cajigas-Du CK, Rios-Colon L, Mediavilla-Varela M, Daniels-Wells TR, Leoh LS, Rojas H, Banerjee H, Martinez SR, Acevedo-Martinez S and Casiano CA: LEDGF/p75 overexpression attenuates oxidative stress-induced necrosis and upregulates the oxidoreductase ERP57/PDIA3/GRP58 in prostate cancer. PloS One. 11:e01465492016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, et al: STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med. 7:315–331. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, et al: GSTP1 loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate. 76:199–206. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Geybels MS, van den Brandt PA, van Schooten FJ and Verhage BA: Oxidative stress-related genetic variants, pro- and antioxidant intake and status, and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 24:178–186. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ding X, Yang DR, Lee SO, Chen YL, Xia L, Lin SJ, Yu S, Niu YJ, Li G and Chang C: TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling. Int J Cancer. 136:955–964. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Debelec-Butuner B, Ertunc N and Korkmaz KS: Inflammation contributes to NKX3.1 loss and augments DNA damage but does not alter the DNA damage response via increased SIRT1 expression. J Inflamm (Lond). 12:122015. View Article : Google Scholar : PubMed/NCBI | |
|
Chaiswing L, Zhong W and Oberley TD: Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med. 67:342–352. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yakes FM and Van Houten B: Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA. 94:514–519. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Khandrika L, Kumar B, Koul S, Maroni P and Koul HK: Oxidative stress in prostate cancer. Cancer Lett. 282:125–136. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ntais C, Polycarpou A and Ioannidis JP: Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 14:176–181. 2005.PubMed/NCBI | |
|
Luchman HA, Villemaire ML, Bismar TA, Carlson BA and Jirik FR: Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia. Am J Pathol. 184:871–877. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jones KJ, Chetram MA, Bethea DA, Bryant LK, Odero-Marah V and Hinton CV: Cysteine (C)-X-C receptor 4 regulates NADPH oxidase-2 during oxidative stress in prostate cancer cells. Cancer Microenviron. Sep 28–2013.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, Duran A, Castilla EA, Metallo CM, Diaz-Meco MT and Moscat J: Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell. 26:121–135. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cao ZG, Xu X, Xue YM and Zhao SL: Comparison of 4-hydroxynonenal-induced p53-mediated apoptosis in prostate cancer cells LNCaP and DU145. Contemp Oncol (Pozn). 18:22–28. 2014.PubMed/NCBI | |
|
Hu C, Yang H, Zhao Y, Chen X, Dong Y, Li L, Dong Y, Cui J, Zhu T, Zheng P, et al: The role of inflammatory cytokines and ERK1/2 signaling in chronic prostatitis/chronic pelvic pain syndrome with related mental health disorders. Sci Rep. 6:286082016. View Article : Google Scholar : PubMed/NCBI | |
|
Strauss AC and Dimitrakov JD: New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nat Rev Urol. 7:127–135. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Polackwich AS and Shoskes DA: Chronic prostatitis/chronic pelvic pain syndrome: A review of evaluation and therapy. Prostate Cancer Prostatic Dis. 19:132–138. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mosli HA, Al-Abd AM, El-Shaer MA, Khedr A, Gazzaz FS and Abdel-Naim AB: Local inflammation influences oestrogen metabolism in prostatic tissue. BJU Int. 110:274–282. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang LL, Huang YH, Yan CY, Wei XD, Hou JQ, Pu JX and Lv JX: N-acetylcysteine ameliorates prostatitis via miR-141 regulating Keap1/Nrf2 signaling. Inflammation. 39:938–947. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pontari MA and Ruggieri MR: Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 172:839–845. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Yuan L, Xiong C, Yin C and Ruan J: Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol. 157:105–113. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Halvorsen BL, Carlsen MH, Phillips KM, Bøhn SK, Holte K, Jacobs DR Jr and Blomhoff R: Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States. Am J Clin Nutr. 84:95–135. 2006.PubMed/NCBI | |
|
Vaz CV, Marques R, Maia CJ and Socorro S: Aging-associated changes in oxidative stress, cell proliferation, and apoptosis are prevented in the prostate of transgenic rats overexpressing regucalcin. Transl Res. 166:693–705. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bae WJ, Ha US, Kim S, Kim SJ, Hong SH, Lee JY, Hwang TK, Hwang SY, Kim HJ and Kim SW: Reduction of oxidative stress may play a role in the anti-inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid-induced cystitis. Neurourol Urodyn. 34:86–91. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Konno S, Chu K, Feuer N, Phillips J and Choudhury M: Potent anticancer effects of bioactive mushroom extracts (Phellinus linteus) on a variety of human cancer cells. J Clin Med Res. 7:76–82. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Prajapati V, Kale RK and Singh RP: Silibinin combination with arsenic strongly inhibits survival and invasiveness of human prostate carcinoma cells. Nutr Cancer. 67:647–658. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gobbo MG, Costa CF, Silva DG, de Almeida EA and Góes RM: Effect of melatonin intake on oxidative stress biomarkers in male reproductive organs of rats under experimental diabetes. Oxid Med Cell Longev. 2015:6145792015. View Article : Google Scholar : PubMed/NCBI | |
|
Yiginer O, Ozcelik F, Inanc T, Aparci M, Ozmen N, Cingozbay BY, Kardesoglu E, Suleymanoglu S, Sener G and Cebeci BS: Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 97:334–340. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma H, Kanwal R, Bhaskaran N and Gupta S: Plant flavone apigenin binds to nucleic acid bases and reduces oxidative DNA damage in prostate epithelial cells. PloS One. 9:e915882014. View Article : Google Scholar : PubMed/NCBI | |
|
Anantharaju PG, Gowda PC, Vimalambike MG and Madhunapantula SV: An overview on the role of dietary phenolics for the treatment of cancers. Nutr J. 15:992016. View Article : Google Scholar : PubMed/NCBI | |
|
Gueritat J, Lefeuvre-Orfila L, Vincent S, Cretual A, Ravanat JL, Gratas-Delamarche A, Rannou-Bekono F and Rebillard A: Exercise training combined with antioxidant supplementation prevents the antiproliferative activity of their single treatment in prostate cancer through inhibition of redox adaptation. Free Radic Biol Med. 77:95–105. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
McGoldrick CA, Jiang YL, Brannon M, Krishnan K and Stone WL: In vitro evaluation of novel N-acetylalaninate prodrugs that selectively induce apoptosis in prostate cancer cells. BMC Cancer. 14:6752014. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar DG, Deepa P, Rathi MA, Meenakshi P and Gopalakrishnan VK: Modulatory effects of Crataeva nurvala bark against testosterone and N-methyl-N-nitrosourea-induced oxidative damage in prostate of male albino rats. Pharmacogn Mag. 8:285–291. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ratnayake R, Liu Y, Paul VJ and Luesch H: Cultivated sea lettuce is a multiorgan protector from oxidative and inflammatory stress by enhancing the endogenous antioxidant defense system. Cancer Prev Res (Phila). 6:989–999. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yonezawa Y, Hada T, Uryu K, Tsuzuki T, Eitsuka T, Miyazawa T, Murakami-Nakai C, Yoshida H and Mizushina Y: Inhibitory effect of conjugated eicosapentaenoic acid on mammalian DNA polymerase and topoisomerase activities and human cancer cell proliferation. Biochem Pharmacol. 70:453–460. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lovegrove C, Ahmed K, Challacombe B, Khan MS, Poper R and Dasgupta P: Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: Analysis of 495,321 participants. Int J Clin Pract. 69:87–105. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Flis A, Suchocki P, Królikowska MA, Suchocka Z, Remiszewska M, Śliwka L, Książek I, Sitarz K, Sochacka M, Hoser G, et al: Selenitetriglycerides-Redox-active agents. Pharmacol Rep. 67:1–8. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin e cancer prevention trial (SELECT). JAMA. 301:39–51. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, et al: Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 306:1549–1556. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Richie JP Jr, Das A, Calcagnotto AM, Sinha R, Neidig W, Liao J, Lengerich EJ, Berg A, Hartman TJ, Ciccarella A, et al: Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: A randomized clinical trial. Cancer Prev Res (Phila). 7:796–804. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jablonska E, Raimondi S, Gromadzinska J, Reszka E, Wieczorek E, Krol MB, Smok-Pieniazek A, Nocun M, Stepnik M, Socha K, et al: DNA damage and oxidative stress response to selenium yeast in the non-smoking individuals: A short-term supplementation trial with respect to GPX1 and SEPP1 polymorphism. Eur J Nutr. 55:2469–2484. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson TA and Wilding G: Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther. 2:797–803. 2003.PubMed/NCBI | |
|
Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G and Liu G: A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Invest New Drugs. 34:225–230. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA and Willett WC: Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 87:1767–1776. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J, et al: Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the alpha-tocopherol beta-carotene cancer prevention study. Am J Clin Nutr. 62 6 Suppl:1427S–1430S. 1995.PubMed/NCBI | |
|
Norrish AE, Jackson RT, Sharpe SJ and Skeaff CM: Prostate cancer and dietary carotenoids. Am J Epidemiol. 151:119–123. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kolonel LN, Nomura AM and Cooney RV: Dietary fat and prostate cancer: Current status. J Natl Cancer Inst. 91:414–428. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Bemis DL, Capodice JL, Anastasiadis AG, Katz AE and Buttyan R: Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer. 52:202–212. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gu Z, Suburu J, Chen H and Chen YQ: Mechanisms of Omega-3 polyunsaturated fatty acids in prostate cancer prevention. Biomed Res Int. 2013:8245632013. View Article : Google Scholar : PubMed/NCBI | |
|
Brown MD, Hart CA, Gazi E, Bagley S and Clarke NW: Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br J Cancer. 94:842–853. 2006. View Article : Google Scholar : PubMed/NCBI |
